Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, ...

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current ...

Pliant Therapeutics, Inc.’s PLRX share price has dipped by 34.81%, which has investors questioning if this is right time to ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

During cell adhesion, integrins are typically thought to require immobilized ligands for spreading. Here, the authors demonstrate that cells can spread and form mature integrin adhesions on fluid ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion specializing in RNA interference (RNAi) technology, is on the cusp of a ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of common stock upon vesting to Delphine Imbert, ...

1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. 2Department of Biological Engineering, Massachusetts Institute of Technology, ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of ...

By analysis of the actin sensor MKL1/MRTFA, we found that its overactivity leads to changed expression of integrins and decreased cell-to-cell contact. This was associated with increased cell ...

During cell adhesion, integrins are typically thought to require immobilized ligands for spreading. Here, the authors demonstrate that cells can spread and form mature integrin adhesions on fluid ...